Bangkok Lab and Cosmetic PCL
SET:BLC
Bangkok Lab and Cosmetic PCL
Other Items
Bangkok Lab and Cosmetic PCL
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bangkok Lab and Cosmetic PCL
SET:BLC
|
Other Items
฿359.5m
|
CAGR 3-Years
1 432%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Mega Lifesciences PCL
SET:MEGA
|
Other Items
-฿275.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
Bangkok Lab and Cosmetic PCL
Glance View
Bangkok Lab & Cosmetic PCL engaes in the provision of pharmaceuticals and health products. The company is headquartered in Bangkok, Bangkok Metropolis. The company went IPO on 2023-06-21. The firm is engaged in the production of medicines and health products by selecting raw materials. The firm has produced more than 100 products. Its products include ZENZERA 200 SUSPENSION, ZENZERA, SYNOVAR UC40, RADIARA, PROCEMINE, FANGO-B, EMBLICOF COUGH MIXTURE, CLINIGEL STERILE, RAQUA FIBROTA, RAQUA COLLAGEN, SYNOVAR UC, SYNOVAR POWDER, NACOXIB, LUTI-BERRY MIXED, ZIGA GEL (orange), ZERTINE SYRUP, VIZO Cream, SPORAXYL CREAM, NORAPHEN, MURHINOL-250 SYRUP, NORFLOXYL 400, NOCID, MURHINOL-250 SYRUP, MUCOBROX, GYNOSTEN CREAM, and GYNOSTEN 500, AROTIKA COOL GEL, ALLERAX-FC, AROTIKA RUB LOTION (SPRAY), Calza c Dietary Supplement, Calza PLUS POWDER Dietary, and Calza-750 TAB FC, among others. Its products are distributed through Bangkok Drug Co., Ltd., Beereach (Thailand) Co., Ltd., Pharmaline Company Limited, Pharma Alliance Company Ltd., and Bangkok Medica Co., Ltd.
See Also
What is Bangkok Lab and Cosmetic PCL's Other Items?
Other Items
359.5m
THB
Based on the financial report for Dec 31, 2024, Bangkok Lab and Cosmetic PCL's Other Items amounts to 359.5m THB.
What is Bangkok Lab and Cosmetic PCL's Other Items growth rate?
Other Items CAGR 3Y
1 432%
The average annual Other Items growth rates for Bangkok Lab and Cosmetic PCL have been 1 432% over the past three years .
